Skip To Main Content
Zhou Yingchun on Muck Rack

Zhou Yingchun

As seen in: Mondaq
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhou

Contact Zhou, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SRS v. Alexion药品许可诉讼案评析--兼论中国创新药企BD合同的风险防控与条款设计

|
By Cai Junxiang, Zhou Yingchun, Yang Ying
| Mondaq
Beijing Jincheng Tongda & Neal Law Firm are most popular: within Corporate/Commercial Law, Transport and Antitrust/Competition Law topic(s) 当前，跨境BD（Business Development）交易已成为中国创新药企实现研发资产变现、对接全球市场、分散商业化风险的核心路径，License Out、NewCo、合作开发、资产收购等各类BD模式，均普遍采用“首付款+里程碑付款+销售分成”的结构化对价安排，其本质是“风险与收益分层分配”的商事契约，许可方（Licensor）通过前期研发投入换取阶段性对价，被许可方（Licensee）则承担后续开发与商业化风险以博取长期收益。然而，在BD交易协议签订后的履约过程中，里程碑付款拒付、研发义务消极履行、被许可方单方终止项目等争议时有发生。...
Open in Who Shared Issue with article?
See all 1 licensed articles (4 Total)